EFFICACY OF THE ANGIOGENESIS INHIBITOR OF BEVACIZUMAB ON THE ARTERIAL SCLEROSIS OF CANCER PATIENTS

Archontoula Michelongona; Konstantinos Toutouzas; Andreas Synetos; Maria Drakopoulou; Georgios Benetos; Flora Zagouri; Aristotle Mpamias; Meletios A Dimopoulos; Dimitris Tousoulis; Christodoulos Stefanadis

doi:10.1016/s0735-1097(14)62124-0

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Report2023

A meta-analysis of VEGF inhibitor efficacy in patients with liver metastases across cancer types.

Jordan W. Conway, Jorja Braden, Serigne Lo, Richard A Scolyer, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Inês Pires da Silva

Article2011

Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma

Peter Olson, Gerald C. Chu, Samuel R. Perry, Olivier Nolan-Stevaux, Douglas Hanahan

Article1998

Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis

Peter Carmeliet

Article2001

Efficacy of concurrent intra-arterial cisplatin and radiation in the treatment of bladder cancer presenting with hydronephrosis

Libni Eapen, David J. Stewart, Rebecca Peterson, C. E, I. Aref, S. Huan, Juanita Crook, Shawn Malone, George Perry, Roanne Segal

Letter2011

Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer

Christodoulos Stefanadis, Andreas Synetos, Dimitris Tousoulis, Eleftherios Tsiamis, Archontoula Michelongona, Flora Zagouri, Aristotle Bamias, Meletios A Dimopoulos, Stella Kyvelou, Ioannis Kapelakis, Konstantinos Toutouzas